Journal
EUROPEAN HEART JOURNAL
Volume 33, Issue 22, Pages 2831-2840Publisher
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehs289
Keywords
CAD; CLARIFY; Gender; Prognosis; Registry; Women
Categories
Funding
- NIHR Cardiovascular Biomedical Research Unit at the Royal Brompton Hospital
- Servier, France
- Servier
- Roche
- Boehringer Ingelheim
- Amgen
- Bayer
- Menarini
- TIMI Group
- DZHK (Deutsches Zentrum fur Herz-Kreislauf-Forschung-German Centre for Cardiovascular Research)
- BMBF (German Ministry of Education and Research)
- NYU School of Medicine
- Sanofi
- Ablynx
- Amarin
- Astellas
- AstraZeneca
- Boehringer-Ingelheim
- BMS
- Daiichi/sankyo
- Eisai
- GSK
- Lilly
- Medtronic
- MSD
- Novartis
- Otsuka
- Pfizer
- Medicines Company
- Vivus
- National Institute for Health Research [NF-SI-0611-10149] Funding Source: researchfish
Ask authors/readers for more resources
Men and women differ in terms of presentation and management in coronary artery disease (CAD). Whether these differences translate into different clinical outcomes in stable CAD is unclear. We analysed data from the international prospective CLARIFY registry to compare cardiovascular clinical outcomes in men and women with stable CAD. We analysed 1-year outcomes in 30 977 outpatients with stable CAD [23 975 (77.4) men; 7002 (22.6) women]. Women were older than men, more likely to have hypertension and diabetes, and less likely to exercise or smoke. They had more frequent angina, but were less likely to have undergone diagnostic non-invasive testing or coronary angiography. Women received less optimized treatment for stable CAD. One-year outcomes were similar for men and women for the composite of cardiovascular death, non-fatal myocardial infarction, or stroke [adjusted rates 1.7 vs. 1.8, respectively, odds ratio (OR) 0.93, 95 confidence interval (CI) 0.751.15]; all-cause death (adjusted 1.5 vs. 1.6, OR: 0.91, 95 CI: 0.721.13); fatal or non-fatal myocardial infarction (adjusted 1.0 vs. 0.9, OR: 0.81, 95 CI: 0.601.08); and cardiovascular death or non-fatal myocardial infarction (adjusted 1.4 vs. 1.4, OR: 0.89, 95 CI: 0.701.12). Fewer women underwent revascularization (2.6 vs. 2.2, OR: 0.77, 95 CI: 0.640.93), although appropriateness was not analysed. The risk profiles of women and men with stable CAD differ substantially. However, 1-year outcomes were similar. Fewer women underwent revascularization. Further research is needed to better understand gender determinants of outcome and devise strategies to minimize bias in the management and treatment of women.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available